http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Humanigen Inc. (HGEN) Appoints John Hohneker to its Board
-
Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors
-
Humanigen Announces Late-Breaking Presentation at the CHEST Annual Meeting Highlighting C-Reactive Protein as a Biomarker for Identifying Patients Most Likely to Benefit from treatment with Lenzilumab
-
Humanigen’s Budget Impact Model Demonstrates Lenzilumab’s Potential Positive Economic Value in Hospitalized COVID-19 Patients
-
Humanigen Signs Contract With Clinigen for Lenzilumab Managed Access Program in Europe
-
Humanigen Announces Participation and Presentation at Multiple Conferences in October
-
Humanigen Submits All Planned Modules for Potential Conditional Marketing Authorization from the UK’s MHRA
-
Humanigen Inc. (HGEN) to Present Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021
-
Humanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021
-
Humanigen Inc. (HGEN) Announces EMA Has Appointed Rapporteur and Co-rapporteur as Part of the Process Related to the Planned Submission of MAA for Lenzilumab
-
Humanigen Announces the European Medicines Agency Has Appointed a Rapporteur and Co-rapporteur as Part of the Process Related to the Planned Submission of a Marketing Authorization Application (MAA) f
-
Humanigen Announces Participation and Presentation at Multiple Conferences in September
-
Humanigen Inc. (HGEN) Announces FDA Denied EMA Request for Lenzilumab in Hospitalized COVID-19 Patients
-
FDA has declined Humanigen’s Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients
-
Humanigen Reports Second Quarter 2021 Financial Results
-
Humanigen Inc. (HGEN) Says Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients
-
Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients
-
Humanigen Inc. (HGEN) Announces NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19
-
NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19
-
Humanigen’s Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab
-
Humanigen (HGEN) announces UK’s MHRA accepts its submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review
-
UK’s MHRA accepts Humanigen’s submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review
-
Humanigen Inc. Added to Russell 3000(R) Index
-
Humanigen Inc. (HGEN) Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency
-
Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA)
-
Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations
-
Humanigen to Present at the 2021 LD Micro Invitational XI
-
Humanigen (HGEN) Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19
-
Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19
-
GM-CSF Gene-Edited CAR-T Data to be Presented at International Society for Cell & Gene Therapy Annual Meeting 2021
-
Humanigen to Present at Jefferies Healthcare Conference
-
Humanigen Inc. (HGEN) and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab
-
Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab
-
Humanigen Reports First Quarter 2021 Financial Results
-
Humanigen (HGEN) Announces Publication of Results From Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating Efficacy, Safety of Lenzilumab in Hospitalized COVID-19 Patients
-
Humanigen Announces Publication of Results From Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab™ in Hospitalized COVID-19 Patients
-
Humanigen (HGEN) Appoints Dr. Adrian Kilcoyne to the role of Chief Medical Officer
-
Humanigen Appoints Dr. Adrian Kilcoyne to the role of Chief Medical Officer
-
Humanigen (HGEN) Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
-
Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
-
Humanigen Inc. (HGEN) Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
-
Humanigen Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
-
Humanigen Inc. (HGEN) Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19
-
Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19
-
Humanigen to Host Conference Call to Report Phase 3 Topline Results of LenzilumabTM in Patients Hospitalized With COVID-19
-
Humanigen Sets Date for Virtual Annual Shareholders Meeting
-
Humanigen Announces $80 Million Loan Facility from Hercules Capital
-
Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
-
Humanigen to Present at Roth Conference
-
Humanigen Inc. (HGEN) Expands its anti-GM-CSF Patent Portfolio
